阿西替尼眼用生物可降解药膜的制备  

Preparation of axitinib in biodegradable drug membranes for ocular surface

作　　者：包志淑[1] 罗梦梦 邓峰[1] 南开辉[1] 

机构地区：[1]温州医科大学附属眼视光医院眼科,浙江温州325027

出　　处：《中国临床药理学杂志》2017年第17期1693-1696,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家重大新药创制专项基金资助项目(2014ZX09303301)

摘　　要：目的为延长药物在眼部的作用时间、增强治疗效果,制备阿西替尼眼用复合药膜用于眼表损伤修复、抗感染及抑制角膜新生血管。方法以阿西替尼为模型药物,用流延成膜技术结合钙离子交联制备载药复合膜,用高效液相色谱(HPLC)法测定药物含量,考察复合药膜体外药物释放。结果复合药膜呈透明状,厚度为(85±11)μm,直径200μm阿西替尼载药膜片载药量为每片(6.5±0.8)μg,溶解性好,角膜组织相容性良好。结论经初步工艺优化,成功制备阿西替尼眼用复合药膜。复合药膜具有药物缓释功能,大大增加药物在眼组织中停留时间。Objective To prolong and enhance the therapeutic effect, the action time of the drug in the eye axitinib composite film was prepared for ocular surface repair, anti -infection and inhibit corneal neovascu- larization. Methods Axitinib as a model, using cast film technology combined with calcium ion cross - linking technology to prepare drug- loaded composite membrane. Determination of drug content by high performance liquid chromatography （HPLC）, detection of drug release in vitro. Results The composite film was transparent, the thickness was （85 ＋ 11 ）μm, the diameter of 200 μm diameter of axitinib drug carrier was （6. 5 ＋ 0. 8 ） μg/film. The drug - loaded films had good corneal dissolvability and histocompatibility. Conclusion After the initial process optimization, the successful preparation of axitinib eye composite film. Composite film has slow release function, greatly increasing the drug in the eye tissue retention time, clinical application prospects.

关 键 词：阿西替尼 复合药膜 体外性能评价 

分 类 号：R97[医药卫生—药品]